Buy Rating Reaffirmed for Nurix Therapeutics: Promising Clinical Data and Increased Approval Probability for NX-5948
Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) and increased the price target ...
Optimistic Buy Rating for Nurix Therapeutics’ NX-5948 Driven by Strong Efficacy in CLL and Strategic Expansion Plans
Analyst Gil Blum from Needham reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price target at ...
Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers?
We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take ...
10 Worst ARK Stocks To Buy According to Short Sellers
For our list of the worst Ark stocks to buy according to short sellers, we ranked the 110 largest holdings in Ark Invest’s Q3 ...
Investing6d
Nurix shares rise on BMO Capital outperform rating
In other recent news, Nurix Therapeutics has been granted PRIME designation by the European Medicines Agency (EMA) for its investigational drug NX-5948, intended for the treatment of adult patients ...
Nurix Therapeutics (NASDAQ:NRIX) Now Covered by Analysts at BMO Capital Markets
BMO Capital Markets started coverage on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a report released on ...
Investing6d
Nurix Therapeutics Inc (NRIX)
On Wednesday, JPMorgan (NYSE:JPM) reiterated its Overweight rating and $30.00 price target on shares of Nurix Therapeutics (NASDAQ:NRIX), a biopharmaceutical company. The firm's ...